A Phase 2, Randomized, Double-blind, Placebo-controlled, 2-part Study To Evaluate EDP-938 Regimens In Subjects Aged 28 Days To 36 Months Infected With Respiratory Syncytial Virus (RSV)
Description
Study subjects will take an oral medication/placebo. Study activities include blood draws, nasal swabs, ECGs, and e-diary entries
MoreDetails
Age
Child
Eligibility
- Age 28 days to 36 months - Diagnosed with RSV infection
Type of Study
Treatment
Locations
Childrens Hospital Colorado
Principal Investigator
Eric Simoes, MD
Study ID
Protocol Number: 23-1409
More information available at ClinicalTrials.gov: NCT04816721
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers